Evidence map›Paper›PMID 34916721›Full record

ArticleNagoya journal of medical science2021

Is area under the curve the best parameter for carboplatin induced emetic risk stratification?

Sachiko Ozone, Kazuya Ichikawa, Masahiro Morise, Akira Matsui, Fumie Kinoshita, Reiko Matsuzawa, Junji Koyama, Ichidai Tanaka, Naozumi Hashimoto

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sachiko OzoneDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuya IchikawaDepartment of Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Masahiro MoriseDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akira MatsuiDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Fumie KinoshitaData Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Reiko MatsuzawaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Junji KoyamaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ichidai TanakaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Naozumi HashimotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPNagoya University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carboplatin (CBDCA)-induced emetic risk is currently classified on the basis of CBDCA-area under the curve (CBDCA-AUC). We investigated the utility of three CBDCA dosage parameters for predicting emesis by CBDCA. Patients with thoracic cancer treated with CBDCA were included. The endpoints were complete response (CR) and total control (TC). CR was defined as no vomiting and no use of rescue medication during the overall assessment period, whereas TC was defined as no vomiting, nausea, nor use of rescue medication during the overall assessment period. The parameters of CBDCA were defined as follows: (1) CBDCA-AUC; (2) CBDCA/body surface area (BSA): the administered dose of CBDCA per body surface area (mg/m

Indexed as

EmeticsAdultAgedAged, 80 and overAntiemeticsCarboplatinFemaleHumansMaleMiddle AgedNauseaRetrospective StudiesRisk AssessmentAntiemeticsCarboplatinEmeticsantiemetic guideline recommendationsantiemetic treatmentcarboplatinchemotherapy-induced nausea and vomiting (CINV)moderate emetic risk regimen

Identifiers

PMID34916721
PMCPMC8648517
OpenAlexW4200591805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.